Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

NCT02539459 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped Extreme toxicity, met toxicity stopping rules

Conditions

Sporadic Angiomyolipomas (AMLs)

Interventions

DRUG: Everolimus

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]